Aporia 02: Long-acting injectable antipsychotics in Indian practice

02 / FieldThe global field, the Indian shelf

The international LAI literature now covers fourteen molecules. The Indian shelf has nine in routine commerce, of which one (olanzapine pamoate) is import-only and effectively unavailable. The six missing formulations are listed in the right column. The cleanest single distinction is between the public-sector pillars (FGA depots, low cost, government supply, high EPS burden) and the private-sector frontier (SGA injections, urban availability, higher cost, lower EPS burden but variable metabolic and prolactin trade-offs).

What this issue does with the shelf

The next two chapters walk the Indian shelf in usage order. Public-sector pillars first, because for most Indian patients the FGA depot is the only realistic LAI, and the four FGAs have meaningfully different positions even though their dose ranges and side-effect profiles overlap. Private-sector frontier second, because the cost ladder runs through this group and because Sun Pharma's paliperidone generic has reshaped what an Indian psychiatrist can offer a patient who cannot afford the brand. The six absent formulations get their own chapter, because the gaps in the Indian shelf are themselves a clinical fact (the patient who would benefit most from a three-monthly or six-monthly schedule cannot have one).

How to use this issue

The chapters that follow are sequenced from canon to clinic. Chapter 03 lists the twelve Maudsley principles that anchor every clinical decision in the document; read it once and refer back. Chapters 04 and 05 walk the Indian shelf drug by drug, with the public-sector pillars (FGA depots) ahead of the private-sector frontier (SGA injections). Chapter 06 documents what India does not have. Chapter 07 is the cost ladder, the single most decision-shaping factor in Indian practice. Chapter 08 collects the practical initiation, switching and missed-dose tables. Chapter 09 is the patient-profile decision matrix, the nine archetypes that recur in OPD work. Chapter 10 covers bipolar maintenance, where the LAI question differs from the schizophrenia question. Chapter 11 closes with the Indian decision frame: IPS CPG 2026, MHCA 2017, NLEM 2022, and the practical consent script.

Every clinical fact is anchored to either the Maudsley 15th edition (the canon), Wei et al. 2022 in JAMA Network Open (the strongest single piece of evidence shifting current practice), the IPS CPG 2026 (the current Indian guideline), the FGA and SGA pricing data from 1mg, PharmEasy and Apollo Pharmacy listings as of May 2026, or the published Indian cohort literature. Where the Notion source we extracted from had errors (the Maudsley year, the Wang versus Ostuzzi attribution on the 2024 SGA-LAI meta-analysis, the non-existent Kane Asia 2023 citation, the Spenzo manufacturer), the corrections are explicit in the reference list.

03 / CanonTwelve Maudsley principles

The Maudsley Prescribing Guidelines, now in its 15th edition (Taylor, Barnes and Young; Wiley, 2025) remain the canonical reference for LAI prescribing in the English-language world.³ Twelve principles from the LAI chapters carry most of the clinical weight and are reproduced or paraphrased verbatim below. The numbering is editorial; the content is Maudsley's.

04 / FGAThe public-sector pillars

The four first-generation depots are the working pharmacology of Indian public-sector psychiatry. They are cheap, familiar, available through DMHP and government tenders, and effective for D2-driven phenomenology. They carry the highest extrapyramidal burden of any LAI class. Their place in modern guidelines has narrowed, but their place in Indian practice has not. The order below tracks the Grover 2019 prescribing survey of 622 Indian psychiatrists.⁸

What the FGA tier does well

All four FGA depots are effective. The relapse-prevention literature has not produced a clear winner among them. The choice between them in Indian practice is driven by cost, supply, and side-effect-profile match to the patient. Fluphenazine is the default where cost is the binding constraint. Haloperidol is the default where the patient was previously on oral haloperidol with good response and where 4-week interval dosing is preferred over 2-week. Flupentixol is the choice where mild activation is desirable (anergic, negative-symptom-dominant chronic schizophrenia). Zuclopenthixol is the choice where sedation is desirable (chronically aggressive or agitated patient on long-term management).

What the FGA tier does badly

The trade-off is movement disorder. All four FGA depots have meaningfully higher rates of acute extrapyramidal symptoms, akathisia and tardive dyskinesia than the SGA LAIs. The Maudsley position is that "none of the individual LAI FGAs has emerged as clearly superior in efficacy" but all carry higher EPS burden than any SGA LAI. The clinical implication: where cost and supply allow, the SGA LAI is preferred for first-episode and younger patients precisely because the lifetime tardive dyskinesia risk on FGA depots accumulates over years.

05 / SGAThe private-sector frontier

The four second-generation injections form the private-sector and tertiary-centre tier of Indian LAI practice. The cost ladder runs steeply through this group. Sun Pharma's Paliris LA, launched as a generic of Invega Sustenna, and Torrent's Tolaz LA olanzapine pamoate have been the single most significant shifts in Indian SGA LAI access in the last five years. The order below tracks Indian use frequency.

What the SGA tier does well

Lower extrapyramidal burden across the class. Lower tardive dyskinesia risk over years of treatment. Better tolerability and adherence over time, with the two linked. Longer dose intervals (monthly versus the 2-week FGA standard) reduce clinic burden. The new-patient and first-episode position has shifted toward SGA LAIs over the last decade, both in Maudsley 15th and IPS CPG 2026. The metabolic and prolactin trade-offs are real but molecule-specific within the SGA tier.

What the SGA tier does badly in India

Cost remains the dominant barrier even after the Sun and Torrent generics. Aripiprazole monohydrate remains import-only via GNH India and effectively out of reach for most patients. Prolactin elevation on paliperidone and risperidone limits use in young women and men sensitive to sexual side effects. Metabolic burden on Tolaz LA accumulates over years; baseline and periodic monitoring of weight, fasting glucose, HbA1c and lipids is mandatory. The PDSS observation requirement on Tolaz LA is the binding logistic constraint that effectively rules the molecule out of routine outpatient practice; tertiary centres with the infrastructure can use it as a defensible first-line choice on cost grounds.

What is coming next

Three shifts in the Indian SGA LAI landscape are worth tracking. First, Lupin's risperidone LAI received United States FDA approval in November 2025 with 180-day competitive generic therapy exclusivity, using its proprietary Nanomi PrecisionSphere platform. This is the first long-acting injectable antipsychotic from an Indian sponsor to receive FDA approval. Lupin has not yet announced an Indian regulatory filing, but the platform technology could extend to paliperidone or aripiprazole generics in the next 2 to 3 years. Second, Tolaz LA pricing at around 1,500 to 3,200 rupees per month makes olanzapine pamoate the cheapest SGA LAI in India by per-month cost; if the PDSS observation infrastructure expands in tertiary centres and large private hospitals, uptake could grow substantially. Third, Sun Pharma's Paliris LA has stabilised paliperidone pricing at roughly half the originator's level, and the field is watching for the next molecule a domestic Indian generic will discount. The likeliest candidate over the next 5 years is paliperidone three-monthly (Trinza) if CDSCO marketing authorisation is granted, which would close the dose-interval gap that currently caps the Indian formulary at monthly dosing.

06 / AbsentSix formulations India does not have

The international LAI literature now treats six formulations as routine or near-routine that the Indian formulary does not list. Two of these are the longer-interval paliperidone formulations. Two are extended aripiprazole formulations. Two are newer risperidone formulations using non-microsphere release technologies. The Indian patient who would benefit most from a quarterly or biannual schedule cannot have one. The gap is structural.

What the six absences cost

The principal clinical loss is the dose-interval frontier. A patient stable on paliperidone monthly for one year has, in Indian practice, no option to graduate to three-monthly or six-monthly. The Maudsley 15th edition position is that the patient stable on PP1M for at least four months on the same dose for the last two months can switch to PP3M; the patient stable on PP3M for at least one cycle can switch to PP6M. Each step reduces injection burden, clinic visit frequency, and total annual cost (despite higher per-dose pricing). The Indian formulary stops at monthly. The clinical implication is that Indian patients on long-term LAI maintenance receive twelve injections per year where European patients receive four or two.

The Lupin wildcard

Lupin received United States FDA approval in November 2025 for a generic risperidone LAI microsphere product, manufactured on its proprietary Nanomi PrecisionSphere platform, with 180-day competitive generic therapy exclusivity in the United States. This is the first long-acting injectable antipsychotic from an Indian sponsor to receive FDA approval. The Indian launch timeline is not yet announced. If Lupin extends the platform to paliperidone or aripiprazole, or if the company files Indian regulatory dossiers for its risperidone product, the Indian SGA LAI landscape could shift in 2026 or 2027. The wildcard is worth tracking.

What each absence costs clinically

The absence of PP3M caps the Indian formulary at monthly dosing for paliperidone. A patient stable on PP1M for one year has, in European or American practice, the option to graduate to PP3M at the same total annual dose, with one quarterly injection replacing three monthly ones. The Indian patient receives twelve injections per year regardless. For patients with poor venous tolerance, work schedules that make monthly clinic visits difficult, or rural addresses requiring half-day travel to the prescribing centre, the cost is concrete.

The absence of PP6M caps the formulary at the quarterly frontier. The 4-year mirror-image studies cited in Maudsley 15th edition support PP6M as a stable maintenance regimen for patients with at least 12 months of prior PP1M or PP3M exposure. Indian patients on long-term LAI maintenance, particularly those with stable but persistent illness who would benefit from minimal clinic contact, have no analogous option.

The absence of Aristada and Asimtufii caps the aripiprazole formulary at monthly dosing for Maintena. Aristada's flexibility (monthly, 6-weekly, or 2-monthly intervals) and Asimtufii's bi-monthly schedule both address the dose-interval frontier from the aripiprazole side. Without them, the Indian patient who tolerates aripiprazole and benefits from its prolactin-and-metabolic-sparing profile receives 12 injections per year where their European or American counterpart could receive 6 or 9.

The absence of Perseris, Uzedy and Rykindo caps the risperidone formulary at the microspheres-with-oral-cover regimen. Uzedy and Rykindo were designed specifically to eliminate Consta's three biggest constraints (cold-chain dependence, oral overlap, two-weekly interval). Indian patients on risperidone LAI continue to face all three.

07 / CostThe Indian cost ladder

The single largest determinant of LAI choice in Indian practice is monthly cost. The ladder below shows the realistic 2026 retail monthly cost of maintenance for each of the LAIs in routine Indian commerce. The bar lengths are scaled to the cost. Prices are from 1mg, Apollo Pharmacy, MedPlus, PharmEasy and IndiaMart institutional listings at time of writing. Government supply (DMHP) covers only fluphenazine reliably.

What this ladder means clinically

The Indian minimum wage in 2026 sits around 8,000 to 12,000 rupees per month depending on state and category. The fluphenazine ladder rung is 0.3% to 0.7% of monthly minimum wage. The Risperdal Consta rung is 90% to 130%. The same molecule with the same evidence base costs the patient at one end of the ladder, in monthly terms, what the patient at the other end of the ladder earns. Insurance coverage does not change this in most Indian outpatient settings. CGHS reimburses listed drugs only; modern SGA LAIs frequently require special sanction. Ayushman Bharat (PMJAY) covers in-patient packages and bundled drug costs but not outpatient LAI maintenance. The cost ladder is the choice ladder for most Indian patients.

The annual cost arithmetic

Twelve months of LAI maintenance, at typical doses, lands in startlingly different brackets. Fluphenazine 25 mg every 2 weeks across a year is roughly 720 rupees of drug cost. Haloperidol decanoate 100 mg every 4 weeks is 1,800 to 2,700 rupees a year. Zuclopenthixol 200 mg every 2 weeks is 13,200 rupees a year. Paliris LA 100 mg monthly is around 29,000 rupees a year. Tolaz LA 300 mg every 4 weeks is around 17,500 rupees a year. Invega Sustenna 150 mg monthly is around 70,000 rupees a year. Risperdal Consta 37.5 mg every 2 weeks is around 100,000 to 120,000 rupees a year. The cheapest annual maintenance is 0.6% of the costliest. For perspective: India's nominal per-capita GDP in 2026 sits around 250,000 rupees, the median monthly household income in Tier 2 and Tier 3 cities around 25,000 to 40,000 rupees, and median schizophrenia-affected household monthly income substantially lower because of illness-related income loss. The Consta annual cost is one-third of median household annual income for the population that most needs LAI treatment.

The Sun Paliris LA generic shifted the SGA LAI floor from a Consta-anchored 100,000 rupees a year to a Paliris-anchored 30,000. Tolaz LA shifted it further, to 17,500 rupees a year at standard 300 mg every 4 weeks dosing. For patients with tertiary care access for the PDSS observation, Tolaz LA can offer the SGA tolerability profile at the FGA-tier cost. The trade-off is not financial; it is the three-hour observation infrastructure.

08 / OverlapThe oral overlap matrix and dose equivalence

Two practical tables anchor every initiation decision: which LAIs require oral overlap and for how long, and what daily oral dose each LAI maintenance dose corresponds to. The first table is operational. The second is conversion.

Oral overlap requirements

Equivalent doses, first-generation LAIs

FGA LAI depot doses are typically calculated as 10 to 20 times the daily oral dose, adjusted for tolerability and patient response.

Equivalent doses, second-generation LAIs

SGA LAI dose conversions are not linear; use manufacturer guidance and clinical response to titrate. Paliperidone palmitate three-monthly conversion (where available) is 3.5 times the last PP1M dose: PP1M 50 to PP3M 175, PP1M 75 to PP3M 263, PP1M 100 to PP3M 350, PP1M 150 to PP3M 525. PP6M conversion (where available) is PP3M 350 to PP6M 700, PP3M 525 to PP6M 1000.

Switching between LAIs

The Maudsley general rule for LAI-to-LAI switching is to give the new depot on the due date of the next dose of the original depot, in place of the original dose, at the equivalent dose calculated through the conversion tables above. Do not give an additional dose of the original; do not double-dose. Three exceptions are worth holding.

Risperdal Consta to anything. Consta has a post-dose peak at week 5. Switching out of Consta requires waiting 2 to 4 weeks after the last RLAI dose was due (i.e. 4 to 6 weeks after the last actual injection) before starting the new LAI, because the late Consta peak would otherwise stack on top of the new agent's initiation phase. The Maudsley caution is explicit on this and it is the single most common LAI-switching error in routine practice.

Anything to paliperidone palmitate. The PP1M loading regimen (Day 1: 150 mg deltoid; Day 8: 100 mg deltoid) is designed to bring plasma levels rapidly to therapeutic range, but if the patient is already at therapeutic levels on another LAI, the standard loading can produce supratherapeutic Cmax and akathisia. Maudsley's practical position: when switching from a stable patient on another LAI to paliperidone, skip the loading regimen and start at the calculated equivalent maintenance dose monthly, deltoid or gluteal.

FGA depot to olanzapine pamoate. Olanzapine pamoate's tolerability profile is meaningfully different (low EPS, high metabolic). The transition over 6 to 8 weeks allows the FGA depot to wash out while the new molecule reaches steady state. Expect transient irritability and sleep disturbance during week 2 to 4 of the switch as the dopaminergic environment shifts from saturated D2 antagonism to the olanzapine 5HT2A:D2 ratio profile. Counsel the patient and family in advance.

Missed doses and re-initiation

The handling of missed LAI doses is one of the most under-taught topics in clinical psychiatry. Maudsley provides molecule-specific guidance; the principles are: never double-dose, calculate the gap from the missed dose date, and either resume at maintenance (short gap) or re-initiate with loading (long gap).

Paliperidone PP1M: Maudsley reminds clinicians that "patients receiving fewer than 12 injections a year have an increased risk of relapse." If a PP1M dose is up to 6 weeks late (i.e. within 2 weeks of the scheduled monthly dose), resume the maintenance dose. If 6 weeks to 6 months late, re-initiate with Day 1 100 mg deltoid + Day 8 100 mg deltoid, then resume monthly. If more than 6 months late, treat as a new patient: full loading regimen (Day 1: 150 mg + Day 8: 100 mg).

Aripiprazole Maintena: If 5 to 6 weeks since last injection, resume maintenance. If 6 to 7 weeks, give next dose with one-day oral aripiprazole 20 mg supplementation. If more than 7 weeks (so more than 4 weeks late on the calendar-monthly schedule), re-initiate with the one-injection-start regimen including 14 days of oral aripiprazole.

FGA decanoates: If the gap is less than half the dose interval, resume maintenance. If between half and one full interval, give the missed dose at the next visit. If more than one full interval, give a half-dose at the next visit and resume the schedule. For haloperidol decanoate specifically, the long half-life (21 days) provides forgiveness; for fluphenazine decanoate (7 to 14 days), the gap is less tolerated and oral cover during the catch-up may be necessary.

Plasma level monitoring

Therapeutic drug monitoring for LAIs is not routine in Indian practice and Maudsley does not advocate it for most patients. Three scenarios change this. First, suspected nonadherence in a patient on Risperdal Consta: one published series found that 9.5% of plasma samples from patients on RLAI contained no risperidone or 9-hydroxy-risperidone, suggesting missed injections were being recorded as administered. A trough plasma level (drawn just before the next injection) clarifies whether the depot is being delivered. Second, renal impairment with paliperidone: dose reduction is required at creatinine clearance below 80 mL/min, and plasma levels confirm therapeutic range during the reduction. Third, concurrent CYP enzyme inducers or inhibitors with aripiprazole: strong CYP2D6 or CYP3A4 modulators (rifampicin, carbamazepine, certain antiretrovirals, certain antifungals) shift aripiprazole metabolism enough to warrant dose adjustment, and plasma levels guide the call. For FGA depots, plasma level monitoring is rarely indicated; the wide therapeutic range and the absence of an unambiguous toxicity threshold make levels of limited clinical use.

09 / ProfileChoosing by patient profile

Nine clinical archetypes recur in Indian LAI decisions. The choice for each is constrained by the Indian cost ladder, but the pharmacological preferences below are the starting positions before cost is applied. Where cost narrows the field to a single FGA depot, the typical fall-back is named.

1. First-episode psychosis

Goals are to minimise relapse, enhance adherence and avoid long-term EPS and metabolic burden. Maudsley and IPS CPG 2026 both support LAI use in first-episode patients once oral tolerability is established. Preferred: aripiprazole LAI (lowest EPS, no prolactin, low metabolic) or paliperidone PP1M (well-tolerated, no oral overlap with loading, monthly). Avoid high-potency FGAs in this group (lifetime tardive dyskinesia risk accumulates). Indian fall-back: paliperidone PP1M as Paliris LA where cost permits; flupentixol decanoate at the lower D2 potency end of the FGA tier where cost binds.

2. Documented or covert nonadherence

Goals are to ensure delivery, allow objective monitoring (missed visit equals missed dose), and minimise relapse. Preferred: paliperidone PP1M (no oral overlap with loading regimen, monthly, deltoid). Avoid Risperdal Consta in this profile precisely because of its three-week oral cover requirement (the patient who does not take oral risperidone for three weeks after the first injection has, in effect, been started on no medication for three weeks). Indian fall-back: haloperidol decanoate where cost binds; fluphenazine decanoate where cost binds harder.

3. History of extrapyramidal symptoms

Goals: minimise D2 antagonism burden. Preferred: aripiprazole LAI (partial D2 agonist, lowest EPS risk of any LAI). Olanzapine pamoate has low EPS risk but PDSS observation is the binding logistic constraint. Avoid: all FGAs, particularly fluphenazine, haloperidol, zuclopenthixol. Indian fall-back: paliperidone PP1M where aripiprazole is unavailable (paliperidone EPS rate is lower than risperidone and substantially lower than any FGA).

4. Prolactin-related side effects

Goals: choose prolactin-sparing options. Maudsley canon (principle 08) is verbatim. Preferred: aripiprazole LAI (may even lower prolactin) or olanzapine pamoate (neutral). Avoid: risperidone microspheres and paliperidone PP1M (highest prolactin elevation among LAIs). Indian fall-back: switching to oral aripiprazole is the practical default where the LAI form is unavailable.

5. Obesity, metabolic syndrome, diabetes

Goals: minimise weight gain and insulin resistance. Preferred: aripiprazole LAI (lowest metabolic). Risperidone LAI is moderate. Avoid: olanzapine pamoate (highest metabolic burden of any LAI). Indian fall-back: haloperidol decanoate has low metabolic risk despite high EPS; the trade-off is movement disorder for cardiometabolic protection.

6. Aggression, repeated relapse, structured supervision needed

Goals: sustained D2 blockade, robust antipsychotic exposure. Preferred: haloperidol decanoate, zuclopenthixol decanoate, or flupentixol decanoate (all strong D2 affinity, all amenable to high-dose long-interval administration). Maudsley's observational edge for zuclopenthixol in time-to-discontinuation may favour it where the long-term aggression risk is dominant. Paliperidone PP1M is acceptable where tolerability is the priority.

7. Need to avoid oral overlap

Goals: establish therapeutic levels quickly, no adherence-dependent oral phase. Preferred: paliperidone PP1M (loading regimen achieves therapeutic levels without oral overlap) or olanzapine pamoate (onset in 2 to 3 days, no oral required, but PDSS observation mandatory). Avoid: Risperdal Consta (3 weeks oral overlap minimum), aripiprazole Maintena (2 weeks oral overlap), FGA depots (1 to 4 weeks oral overlap).

8. Special populations: pregnancy, elderly, renal impairment

Pregnancy: NICE recommends avoiding depot preparations in women planning pregnancy unless previously responsive to one. Best reproductive safety data among LAIs: haloperidol decanoate (most studied) and aripiprazole LAI (limited data, oral form considered relatively safe). Paliperidone-specific warning: detectable in plasma up to 18 months after a Trevicta dose; the prolonged half-life is the contraindication, not a single property of the molecule. Elderly: start at lowest possible dose, longer intervals; aripiprazole one-injection-start preferred over two-injection-start in over-65s. Renal impairment: paliperidone requires dose reduction in moderate impairment (creatinine clearance 50 to 80 mL/min: 50 mg loading day 1, 25 mg day 8, then 25 to 75 mg monthly). Aripiprazole LAI requires no dose adjustment in renal or hepatic impairment but adjustment with strong CYP2D6 or CYP3A4 modulators.

9. Rural setting, limited healthcare access

Goals: minimise visit frequency, ensure long duration of effect. Preferred: paliperidone PP3M where available (it is not, in India). Indian fall-back: flupentixol decanoate or zuclopenthixol decanoate at every-4-week interval; haloperidol decanoate at every-4-week interval. The absence of PP3M and PP6M from the Indian formulary is most clinically costly in this profile, where the patient might most benefit from quarterly or biannual dosing.

10 / BipolarLAIs in bipolar maintenance

Long-acting injectable antipsychotics in bipolar disorder are a smaller and more specific literature than the schizophrenia evidence base, with three findings that residents should commit to memory. The Maudsley 15th edition reproduces and extends them from the 14th.

The three findings

First, risperidone LAI and aripiprazole LAI both reduce the risk of recurrence of manic and hypomanic episodes versus placebo, robustly. The effect size is consistent across published trials of both agents.

Second, risperidone LAI and aripiprazole LAI have no effect on the risk of depressive recurrence in bipolar disorder. This is Maudsley canon (principle 12), verbatim. The protection is mood-direction-specific. LAIs prevent the next manic episode; they do not prevent the next depressive episode. A patient with a predominantly depressive course on bipolar maintenance gains less from an LAI than a patient with a predominantly manic course.

Third, there is no evidence to support the benefit of LAIs over oral antipsychotic treatment in bipolar maintenance. The Maudsley position is that LAIs in bipolar disorder are an option for adherence-related concerns, not a pharmacologically superior alternative. The 2017 FDA approval of Abilify Maintena for bipolar I maintenance monotherapy, extended in 2023 to Abilify Asimtufii, established aripiprazole LAI as the only LAI formally indicated for bipolar maintenance in regulatory terms.

First-generation LAIs in bipolar disorder

Support is weak. Very limited evidence suggests FGA LAIs may reduce manic recurrence; they do not prevent depression and may worsen it. The clinical implication for Indian practice is that the FGA tier, despite being cheap and available, is a poor fit for bipolar maintenance. A patient with bipolar I and a history of depressive episodes is more likely to do worse on haloperidol decanoate than on no LAI; the depressogenic potential of high-potency D2 blockade is non-trivial.

What this means in Indian bipolar practice

The clinically defensible LAI choices for bipolar maintenance in India narrow to:

• Aripiprazole monohydrate (Maintena) as the first choice on pharmacological grounds (FDA-approved indication, no prolactin, no metabolic burden, no depressogenic D2-saturation effect). Constrained by import-only availability.
• Paliperidone PP1M as the practical second choice where aripiprazole LAI is unavailable, on the grounds of monthly dosing and tolerability, but with the caveat that the manic-recurrence-only protection still holds.
• Risperidone microspheres (Consta) as a third choice in patients previously stable on oral risperidone with predominantly manic course.

The FGA tier is not recommended for bipolar maintenance even where cost otherwise binds the choice. A bipolar patient with both adherence concerns and a binding cost constraint is, in Indian practice, a patient for whom an LAI strategy may not be the right answer; oral mood stabiliser (lithium or valproate) with structured adherence support may be a better fit than a depot antipsychotic with a depressogenic edge.

LAIs alongside lithium and valproate

Bipolar maintenance in Indian practice is mood-stabiliser-led, with an SGA antipsychotic added for adherence, mania-recurrence protection, or persistent psychotic features between episodes. The LAI question therefore usually arises as: "this patient is on lithium 900 mg per day with three breakthrough manic episodes in two years; should we add an LAI?" The Maudsley position is that the LAI is a reasonable adjunct in this scenario, but the mood stabiliser remains the anchor of relapse prevention, particularly against the depressive pole. Lithium plasma monitoring (target 0.6 to 0.8 mmol/L for maintenance), renal function and thyroid function should be tracked at standard intervals regardless of LAI co-prescription. The combination of lithium plus aripiprazole monohydrate LAI is well-tolerated in published series and is the most defensible bipolar-maintenance LAI regimen on current evidence. Lithium plus paliperidone PP1M carries higher prolactin burden; lithium plus Tolaz LA carries higher metabolic burden and requires close glucose and lipid monitoring.

When LAI is not the answer in bipolar

Three bipolar profiles where an LAI is not the right answer. First, the predominantly depressive course: LAIs do not protect against depression; adding one to a patient with three depressive and one manic episode over five years offers little against the dominant pole. Second, the rapid-cycling presentation: long half-life formulations make dose adjustments slow and limit the clinical responsiveness needed in rapid cycling; lithium plus lamotrigine with structured adherence is often a better fit. Third, the postpartum or pregnancy-planning patient: the long half-life of LAIs is precisely what makes them problematic when reproductive considerations change. NICE recommends avoiding LAIs in women planning pregnancy unless there is a clear history of nonadherence and previous LAI response; the paliperidone-specific warning (drug detectable in plasma up to 18 months after Trevicta) is the strongest case in point.

11 / IndiaThe Indian decision frame

Four pieces of Indian-specific infrastructure shape every LAI decision: the Indian Psychiatric Society's 2026 schizophrenia clinical practice guideline, the Mental Healthcare Act 2017's capacity and consent provisions, the National List of Essential Medicines 2022 inclusion or absence, and the cold-chain and trained-staff reality of Tier 2 and Tier 3 city practice.

The IPS CPG 2026 position

The Indian Psychiatric Society's clinical practice guideline for management of schizophrenia, published by Sahoo and colleagues in Indian Journal of Psychiatry in January 2026, reverses the older "last-resort" framing for LAIs.⁹ The current IPS position is that LAIs should be offered proactively after the first relapse or when nonadherence is detected, not after multiple failed oral trials. The CPG explicitly endorses LAI use in first-episode psychosis where oral tolerability has been established. Recommended agents are tiered: in resource-limited settings, the four FGA depots (haloperidol, fluphenazine, flupentixol, zuclopenthixol decanoate); where SGAs are available, risperidone microspheres, paliperidone palmitate, aripiprazole monohydrate, olanzapine pamoate. The IPS guideline is more aligned with Wei 2022 and Maudsley 15th than the 2010s-era practice it replaces. Indian psychiatric residents trained in the past decade should expect the guideline frame to be tested in their exit examinations from 2026 onward.

The Mental Healthcare Act 2017 capacity rule

The MHCA 2017 does not address LAIs by name. The Act's general framework applies. Three sections matter for LAI prescribing.¹¹

Sections 86 to 89 establish that capacity is decision-specific. A patient with capacity may refuse an LAI even if the clinician recommends it. Sustained refusal of an LAI in a patient with capacity cannot be overridden by clinical judgement; it can only be revisited if the patient's capacity changes.

Section 14 permits advance directives. A patient may specify acceptance or refusal of injectable formulations in their advance directive; this binds future treatment unless the patient revokes it with capacity.

Sections 89 and 90 (supported admission of up to 30 days and beyond 30 days) permit treatment over patient objection only if the patient lacks capacity and the nominated representative consents. An LAI under supported admission is permissible but carries high audit risk; documentation of capacity assessment, nominated representative consent, and Mental Health Review Board notification beyond 30 days is mandatory. Unlike emergency ECT (Section 94) and psychosurgery (Section 95), LAIs are not subject to explicit MHCA prohibition, but the same procedural safeguards apply in spirit.

The NLEM 2022 gap

The National List of Essential Medicines 2022, reviewed by Parmar and colleagues from the psychiatric perspective in Indian Journal of Psychological Medicine 2023, lists sixteen psychotropics.¹² Among the LAIs, only fluphenazine decanoate (injection 25 mg/mL) is included. Haloperidol injection 5 mg/mL (short-acting) is listed; haloperidol decanoate is not. Risperidone, olanzapine and aripiprazole are listed in oral forms only; none of the SGA LAIs is on NLEM 2022. The clinical implication is that district mental health programme free-drug supply yields oral antipsychotics plus haloperidol short-acting injection plus fluphenazine decanoate, but no other LAI. The Indian patient who would benefit from paliperidone PP1M at the public-sector level cannot have it through DMHP supply. The Paliris LA generic has reduced the out-of-pocket burden but has not put the molecule on the essential medicines list.

The cold-chain and infrastructure reality

Risperidone microspheres (Consta) require validated cold-chain transport. In Tier 2 and Tier 3 cities, reliable cold-chain availability is limited to large private hospitals and specialty centres. Paliperidone palmitate (PP1M and PP3M) is aqueous suspension and similarly cold-chain dependent, though slightly more tolerant of transport excursion. Oil-based FGA depots (haloperidol, fluphenazine, flupentixol, zuclopenthixol decanoate) tolerate ambient storage and are the LAIs of choice where cold-chain reliability is the binding constraint. Olanzapine pamoate's three-hour post-injection observation requirement is the single largest infrastructural barrier; the staffing model required to deliver this routinely is not present in most Indian outpatient setups.

A consent script for the OPD

A practical model script for proposing an LAI to a patient and family member during the OPD interview, adapted from MHCA 2017 capacity provisions and informed-consent best practice. The script translates well into Hindi, Kannada and Marathi; the structure is the same regardless of language. Three components: explanation of the rationale, explanation of the trade-offs, and the explicit invitation to refuse.

When to refer to a tertiary centre

Three LAI decisions warrant tertiary referral rather than initiation at district-level outpatient setups. Olanzapine pamoate (Tolaz LA) initiation: the three-hour PDSS observation requirement is the absolute indication for tertiary referral; this should not be initiated at a centre without a monitored injection room with resuscitation capability. Aripiprazole monohydrate (Maintena): import availability and cost considerations align with tertiary or large private-hospital practice, where the supply chain through GNH India or specialty distributors is established. LAI initiation in pregnancy or postpartum: the reproductive safety considerations, peripartum coordination with obstetric care, and intensive monitoring requirements all argue for tertiary-centre management. Routine FGA depot maintenance, Paliris LA initiation, and stable patient continuation can be done at district-level psychiatry OPDs with appropriate training and supply.

ReferencesSources